BRPI0812384A2 - Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 - Google Patents

Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21

Info

Publication number
BRPI0812384A2
BRPI0812384A2 BRPI0812384-5A2A BRPI0812384A BRPI0812384A2 BR PI0812384 A2 BRPI0812384 A2 BR PI0812384A2 BR PI0812384 A BRPI0812384 A BR PI0812384A BR PI0812384 A2 BRPI0812384 A2 BR PI0812384A2
Authority
BR
Brazil
Prior art keywords
treatment
fgf21
diagnostic
methods associated
disease
Prior art date
Application number
BRPI0812384-5A2A
Other languages
English (en)
Inventor
Cheng Liu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0812384A2 publication Critical patent/BRPI0812384A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0812384-5A2A 2007-05-22 2008-05-20 Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 BRPI0812384A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93951207P 2007-05-22 2007-05-22
PCT/US2008/006481 WO2008153705A2 (en) 2007-05-22 2008-05-20 Methods of treating, diagnosing and detecting fgf21-associated disorders

Publications (1)

Publication Number Publication Date
BRPI0812384A2 true BRPI0812384A2 (pt) 2014-12-02

Family

ID=39739850

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812384-5A2A BRPI0812384A2 (pt) 2007-05-22 2008-05-20 Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21

Country Status (11)

Country Link
US (1) US20110002845A1 (pt)
EP (1) EP2152737A2 (pt)
JP (1) JP2010529954A (pt)
KR (1) KR20100017169A (pt)
CN (1) CN101679501A (pt)
AU (1) AU2008262450A1 (pt)
BR (1) BRPI0812384A2 (pt)
CA (1) CA2687746A1 (pt)
EA (1) EA200901550A1 (pt)
MX (1) MX2009012625A (pt)
WO (1) WO2008153705A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
MX2010013333A (es) 2008-06-04 2011-04-05 Amgen Inc Mutantes fgf21 y usos de los mismos.
EA032727B1 (ru) 2008-10-10 2019-07-31 Амген Инк. Мутантный резистентный к протеолизу полипептид fgf21 и его применение
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
WO2010139741A1 (en) * 2009-06-04 2010-12-09 Novartis Ag Fgf-21 for treating cancers
WO2010148142A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
CN102656266B (zh) * 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 具有改变的受体特异性的嵌合成纤维细胞生长因子
JP2013512672A (ja) 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
KR101900962B1 (ko) * 2010-04-09 2018-09-20 큐알엔에이, 인크. 섬유아세포 성장 인자 21 (ｆｇｆ21)에 대한 자연 안티센스 전사체의 저해에 의한 섬유아세포 성장 인자 21 (ｆｇｆ21) 관련된 질환의 치료
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CN102296110B (zh) * 2011-07-18 2016-08-10 西北农林科技大学 一种检测黄牛fgf21基因单核苷酸多态性的方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
BR112017005110A2 (pt) 2014-09-16 2018-01-23 Regeneron Pharma anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
US9955802B2 (en) 2015-04-08 2018-05-01 Fasteners For Retail, Inc. Divider with selectively securable track assembly
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN107449715B (zh) * 2016-05-30 2021-01-22 康建胜 活细胞胞内代谢分析仪及其分析方法
MX382035B (es) 2016-11-17 2025-03-13 Regeneron Pharma Uso de un inhibidor angptl8 en la preparación de un medicamento para tratar la obesidad.
US20200000880A1 (en) * 2017-02-01 2020-01-02 Children's Medical Center Corporation Fgf21 compositions for treatment or prevention of neovascularization of the eye and methods therefor
JP7022145B2 (ja) * 2017-04-04 2022-02-17 ジェネンテック， インコーポレイテッド 線維芽細胞活性化タンパク質（ｆａｐ）によって認識される基質とその使用方法
JP7066540B2 (ja) * 2018-06-14 2022-05-13 株式会社日立製作所 デジタルｐｃｒの測定方法および測定装置
CN110279847B (zh) * 2019-05-17 2023-04-14 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 Fgf21在制备促进超长随意皮瓣存活的药物中的应用
CN110257512A (zh) * 2019-05-20 2019-09-20 上海交通大学医学院 用于luminal型和HER2型乳腺癌诊断、治疗及预后的标志物和组合物
CN111420030B (zh) * 2020-05-12 2021-01-29 江南大学 Fgf21在制备用于治疗结直肠癌药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7368100A (en) * 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
US6716626B1 (en) * 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1628101A (en) * 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
EP1666497A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
AU2003270424A1 (en) * 2002-09-09 2004-03-29 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1831371A2 (en) * 2004-12-14 2007-09-12 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006078463A2 (en) * 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
JP2006246823A (ja) * 2005-03-11 2006-09-21 Kyoto Univ 造血因子としてのＦｇｆ２１の使用

Also Published As

Publication number Publication date
WO2008153705A2 (en) 2008-12-18
CA2687746A1 (en) 2008-12-18
EA200901550A1 (ru) 2010-10-29
US20110002845A1 (en) 2011-01-06
CN101679501A (zh) 2010-03-24
KR20100017169A (ko) 2010-02-16
AU2008262450A1 (en) 2008-12-18
EP2152737A2 (en) 2010-02-17
WO2008153705A3 (en) 2009-03-05
JP2010529954A (ja) 2010-09-02
MX2009012625A (es) 2009-12-07

Similar Documents

Publication Publication Date Title
BRPI0917567A2 (pt) tratamento de doença respiratória
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
IL212856A (en) Human antibodies against human tissue factor, conjugates and uses thereof
BRPI0722004A2 (pt) Posto de saúde.
BRPI0807896A2 (pt) Fórceps bipolares não-aderentes.
BRPI0922322A2 (pt) endoscópio com uma porção curvada
BRPI0822633A2 (pt) Desinfetante, e, método de esterilização.
HUE071237T2 (hu) Fabry-kór kezelési lehetõségei
BRPI0816794A2 (pt) Tratamento pós-colheita.
BRPI0923409A2 (pt) cabeça de escova de dentes, e, escova de dentes.
BRPI0815889A2 (pt) Análise do perfil de glicosilação.
FR2917962B1 (fr) Electrocardiographe ambulatoire evenementiel.
BRPI0822572A2 (pt) Terapia guiada por imagem de doença moicardial, composição manufaturamento e aplicações
BRPI0820101A2 (pt) Combinação, e, aparelho que cobre a cabeça de estetoscópio
BRPI0822381A2 (pt) Agulha de coleta de sangue com sinalização
DE602007001361D1 (de) Sphinkterotom mit Zweifachkrümmung
SI2432798T1 (sl) Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postopki izdelave in uporaba pri zdravljenju bolezni
ATE494839T1 (de) Gewebeentnahme
FI20075181L (fi) Hammashoitokone, jossa on ohjelmoitavissa olevia toimintoja
IL199807A0 (en) Biometric diagnosis
DK1863899T3 (da) Hudbehandlingspræparater
BRPI0923652A2 (pt) diagnóstico e tratamento de câncer usando anticorpo anti-lgr7

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]